KRYS Krystal Biotech Inc

Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025

Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025

PITTSBURGH, April 17, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025, prior to the open of U.S. markets.

The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, May 6, 2025, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: .

For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at .

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit , and follow @KrystalBiotech on and (formerly Twitter).

CONTACT

Investors and Media:

Stéphane Paquette, PhD

Krystal Biotech

            



EN
17/04/2025

Underlying

KRYSKrystal Biotech Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Krystal Biotech Inc

 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Present at Upcoming Scientific Conferences

Krystal Biotech to Present at Upcoming Scientific Conferences PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June. Presentation details are outlined below. American Society of Gene & Cell Therapy (ASGCT) 28th Annual MeetingInvited Oral Presentation Title: HSV-1 as a vector system for targeting respiratory tissues in genetic pulmonary diseasePresenter: Trevor Parry, PhDDate and Time: May 17, 202...

April 24, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Report First Quarter 2025 Financial Results on May ...

Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025 PITTSBURGH, April 17, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, May 6, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: . For those unabl...

April 17, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- (“Jeune”), a wholly owned subsidiary of (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well ...

April 7, 2025 1 EN
Free Trial
KRYS Krystal Biotech...

Krystal Biotech Inc: 2 directors

Two Directors at Krystal Biotech Inc sold/sold after exercising options 50,000 shares at 177.791USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...

KRYS KRYSTAL BIOTECH INC
03/14/25 March 14, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Tr...

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa EC approval decision anticipated in second quarter of 2025 PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s)  that its Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the European Commission (EC) to approve VYJUVEK® (beremagene geperpavec-svdt, or B-VEC) for the treatment of wounds in...

February 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch